Daxor Co. (NASDAQ: DXR) had its price target raised by analysts at Ascendiant Capital Markets from $24.50 to $24.75. They now have a "buy" rating on the stock.
Daxor Corporation - Closed End Fund (DXR)
NASDAQ:AMEX Investor Relations:
daxor.com/investors
Company Research
Source: MarketBeat
Impact Snapshot
Event Time:
DXR
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
DXR alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
DXR alerts
High impacting Daxor Corporation - Closed End Fund news events
Weekly update
A roundup of the hottest topics
DXR
News
- Daxor Expands Blood Volume Analysis Technology Across Midwest, Wisconsin, and New Jersey Healthcare NetworksGlobeNewswire
- Daxor Co. (NASDAQ: DXR) had its price target raised by analysts at Ascendiant Capital Markets from $24.75 to $25.00. They now have a "buy" rating on the stock.MarketBeat
- https://seekingalpha.com/article/4765553-daxor-corporation-dxr-q4-2024-earnings-call-transcript [Seeking Alpha]Seeking Alpha
- Daxor Corporation Reports Increase in NAV to $7.25 Per Share and 116.5 Percent Increase in Unaudited Revenue of Operating Division for the Year Ended December 31, 2024GlobeNewswire
- Daxor Corporation to Host Investor Conference Call to Discuss Fiscal Year 2024 Financial Results and Provide a Corporate Update on March 6, 2025GlobeNewswire
DXR
Analyst Actions
- 3/17/25 - Ascendiant Capital
DXR
Sec Filings
- 3/27/25 - Form 4
- 3/20/25 - Form 4/A
- 3/20/25 - Form 4
- DXR's page on the SEC website